Filing Overview
Registrant: NLS Pharmaceutics Ltd. (the request metadata identifies Newcelx Ltd., which does not match the filing text). This Form 6-K was furnished for April 2022 and reports an event dated April 1, 2022. The registrant files annual reports on Form 20-F.
Business Context and Reporting Period
The filing furnishes a press release titled “NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements.” The press release is filed as Exhibit 99.1 and incorporated by reference into the registrant’s Form F-3 registration statement.
Financial and Operating Metrics
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
- The filing does not provide a financial reporting period or comparative-period results.
Material Changes, Guidance, and Risks
- The material reported event is receipt of a notice of deficiency relating to Nasdaq continued-listing requirements.
- The text provided does not state the specific listing deficiency, Nasdaq’s deadline, the required remediation, or the potential consequences.
- No financial guidance, operating outlook, management commentary, contingencies, or unusual financial items are provided in the filing text.
Investor Verification Items
- Review Exhibit 99.1 for the specific Nasdaq continued-listing deficiency and applicable compliance deadlines.
- Verify whether the registrant submitted a remediation plan, requested a hearing, or received subsequent Nasdaq correspondence.
- Confirm the registrant identity, because the provided metadata names Newcelx Ltd., while the filing identifies NLS Pharmaceutics Ltd.
- Review subsequent SEC filings for the status of Nasdaq compliance and any related financing or liquidity implications.